Dr Howard Lightfoot | Principal Bioinformatician

Lightfoot, Howard

Howard develops and maintains the informatics requirements for the Garnett group: from lab tracking to the statistical analysis and presentation of results for the GDSC project. With a background in IT, he completed a PhD in cell biology and bioinformatics at the University of Warwick before joining the Sanger Institute in 2012.

Publications

  • Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models.

    van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C et al.

    Nucleic acids research 2019;47;D1;D923-D929

  • A Landscape of Pharmacogenomic Interactions in Cancer.

    Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP et al.

    Cell 2016;166;3;740-754

  • Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

    Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H et al.

    Nucleic acids research 2013;41;Database issue;D955-61

  • Multilevel models improve precision and speed of IC50 estimates.

    Vis DJ, Bombardelli L, Lightfoot H, Iorio F, Garnett MJ and Wessels LF

    Pharmacogenomics 2016;17;7;691-700

  • A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

    Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M et al.

    Cell 2016;167;1;260-274.e22

  • Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models.

    van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C et al.

    Nucleic acids research 2019;47;D1;D923-D929

  • Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

    Li X, Francies HE, Secrier M, Perner J, Miremadi A et al.

    Nature communications 2018;9;1;2983

  • GDSCTools for mining pharmacogenomic interactions in cancer.

    Cokelaer T, Chen E, Iorio F, Menden MP, Lightfoot H et al.

    Bioinformatics (Oxford, England) 2018;34;7;1226-1228

  • Intra-tumour diversification in colorectal cancer at the single-cell level.

    Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB et al.

    Nature 2018;556;7702;457-462

  • Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

    Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S et al.

    eLife 2018;7

  • High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.

    Williams SP, Barthorpe AS, Lightfoot H, Garnett MJ and McDermott U

    Scientific data 2017;4;170139

  • A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

    Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M et al.

    Cell 2016;167;1;260-274.e22

  • A Landscape of Pharmacogenomic Interactions in Cancer.

    Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP et al.

    Cell 2016;166;3;740-754

  • Multilevel models improve precision and speed of IC50 estimates.

    Vis DJ, Bombardelli L, Lightfoot H, Iorio F, Garnett MJ and Wessels LF

    Pharmacogenomics 2016;17;7;691-700

  • Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

    Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H et al.

    Nucleic acids research 2013;41;Database issue;D955-61

Lightfoot, Howard